Business
Launch of products at Vitafoods 2017
Launch of products at Vitafoods 2017.
About this update from Optibiotix Health Plc
[{"type":"text","content":"\n \nRNS Number : 0730Y OptiBiotix Health PLC 01 March 2017 \n\nOptiBiotix Health plc\n(\"OptiBiotix\" or the \"Company\")\n \nLaunch of products at Vitafoods 2017\n \nOptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces it plans to launch products containing its cholesterol reducing strain (LPLDL®) at the Vitafoods Europe Trade Show (\"Vitafoods\") in Geneva on the 9-11 May 2017. The trade show provides opportunities to connect with 16,500 industry decision makers from the supplements, nutraceutical, functional food and beverage industries. The event is viewed as one of the world's leading trade fairs for the food and drinks industry.\n \nOptiBiotix will be launching the first of its range of heart health products including:-\n \n· CholBiome™: a proprietary formulation containing LPLDL® to reduce cholesterol levels and blood pressure\n· CardioBiome™: a proprietary formulation containing LPLDL® to reduce a wide range of cardiovascular disease factors and improve long term heart health\n \nThe Company will also exhibit its SlimBiome® weight management technology in the New Products Zone at Vitafoods. This is the first time this product has been exhibited to an industry audience outside the UK.\n \nThe launch of heart health products follows a period in which OptiBiotix has been extending its patent portfolio, registering new trademarks (e.g. LPLDL®, Cholbiome™, Cardiobiome™) and presenting its science for peer review in publications and at scientific conferences. This has paralleled discussions with manufacturers, formulators and distribution partners to develop a range of product formulations to meet different application needs in international markets. The overall aim of this work has been to increase industry awareness of LPLDL® to develop numerous opportunities with national and international partners who have rights to specific formulations and presentations in different territories. This could create the potential for revenue streams at multiple points in the value chain including sale of the strain as an ingredient by manufacturers and royalties from th...